Mutation of CEP72 Gene May Predispose Patients to Hepatotoxicity. Issue 7 (October 2020)

• Record Type: Journal Article
• Authors: Pham, Robin; Hoeft, Alice; Roberts, Carol; Hamby, Tyler; Maloy, Charles; Ray, Anish
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 7(2020)
• Publication Date: 2020-10
• Subjects: acute lymphoblastic leukemia -- 6-mercaptopurine toxicity -- CEP72 risk allele -- TPMT -- vincristine toxicity; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001568
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Drug toxicities during treatment of acute lymphoblastic leukemia play a pivotal role in influencing the outcome as certain toxicities may impair treatment compliance. Polymorphisms in CEP72 have been linked to increased incidence of vincristine-induced toxicities, namely peripheral neuropathy. We hypothesize that polymorphisms in the same gene may increase a patient's risk of developing hepatotoxicity when receiving potentially hepatotoxic agents during chemotherapy. This report describes hepatotoxicity that first developed during consolidation in a patient homozygous for the CEP72 risk alleles. Bilirubin levels normalized following dose reduction of 6-mercaptopurine. The patient continues to tolerate maintenance therapy at a reduced dose of 6-mercaptopurine.